title: Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.
abstract: With the growing complexity of treatment options for chronic lymphocytic leukemia (CLL) and variables that influence the underlying biology of this disease, providing allogeneic stem cell transplant (alloSCT) to appropriate candidates poses a challenge for transplant physicians. Novel small molecule inhibitors hold unprecedented promise for poor-risk subgroups, which will likely alter decision-making and referral patterns for transplant. In this review, we analyze what is known and may still remain true about indications for transplant based on outcomes reported in the literature recently and over the last decade.
authors.affiliation: Division of Hematology and Oncology, BMT and CT Program, Department of Internal Medicine, UAB Hosptial, University of Alabama at Birmingham Comprehensive Cancer Center , Birmingham, AL , USA.
authors.forename: Racquel D
authors.initials: RD
authors.lastname: Innis-Shelton
authors.forename: Randall S
authors.initials: RS
authors.lastname: Davis
authors.forename: Lawrence
authors.initials: L
authors.lastname: Lamb
authors.forename: Shin
authors.initials: S
authors.lastname: Mineishi
mesh_terms: D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D011379:Prognosis; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
keywords: Allogeneic; chronic lymphocytic leukemia; stem cell transplant